The Dominican Republic has begun administering a nonavalent vaccine to protect the population against nine different serotypes of the Human Papillomavirus [1].
This rollout represents a significant escalation in public health efforts to reduce the incidence of HPV-related cancers. By targeting a broader range of virus types, health officials aim to provide more comprehensive protection for the public.
Dr. Manuel Tiberio Ayala, an epidemiologist at the Dirección de Salud, said the risks and prevention of the virus during a recent health program on RCN Televisión [2]. The initiative is designed to inform the public and dispel myths regarding the vaccine to increase uptake [3].
Data on the prevalence of the virus varies among health sources. Some reports indicate that approximately 43% of sexually active people are infected with HPV [4]. Other data suggests the virus can affect up to 80% of the population [5].
Health officials in Santo Domingo are emphasizing the role of vaccination as a primary means of prevention. The nonavalent version of the vaccine is specifically designed to cover nine serotypes [1].
Regional efforts to combat the virus have existed for years. Mexico, for example, has been vaccinating girls between the ages of 12 and 16 against HPV since 2008 [6].
The Dominican Republic's current strategy focuses on integrating this new vaccine into the national health system to lower the long-term risk of cervical, and other HPV-linked cancers [3].
“The nonavalent vaccine protects against nine HPV serotypes”
The transition to a nonavalent vaccine in the Dominican Republic indicates a shift toward higher-efficacy prevention tools that cover more viral strains than previous iterations. Given the wide disparity in reported infection rates—ranging from 43% to 80%—the broader coverage of nine serotypes is intended to mitigate the risk across a larger segment of the population.
